報價延遲最少15分鐘:2025/09/18 16:57 EDT
盤後時段
|
||||
|
1.5 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.62/--
|
|
企業價值
475.50M
|
| 資產負債 |
|
每股賬面淨值
4.19
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
490.74M
|
|
每股收益
16.95
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/18 16:57 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment. |
